Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data

BMC Infectious Diseases

Volumn 12, Issue , 2012, Pages

  Strutton, David R ^a   Farkouh, Raymond A ^a   Rubin, Jaime L ^b   McGarry, Lisa J ^b   Loiacono, Paul M ^a   Klugman, Keith P ^c   Pelton, Steven I ^d   Gilmore, Kristen E ^b   Weinstein, Milton C ^e  

^a PFIZER INC   (United States)

^b OPTUM   (United States)

^c EMORY UNIVERSITY   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

13 valent; Catch up vaccination; PCV13; Pneumococcal; Pneumococcal conjugate vaccine

Indexed keywords

PNEUMOCOCCUS VACCINE;

ACUTE OTITIS MEDIA; ARTICLE; CATCH UP PROGRAM; CHILD; HEALTH INSURANCE; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; PNEUMOCOCCAL INFECTION; PNEUMOCOCCAL MENINGITIS; PNEUMONIA; PROBABILITY; SCHOOL CHILD; SENSITIVITY ANALYSIS; UNITED STATES; VACCINATION;

CHILD, PRESCHOOL; DRUG UTILIZATION; FEMALE; HUMANS; INFANT; MALE; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; UNITED STATES;

EID: 84864498079     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-12-175     Document Type: Article

References (7)

1. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children - Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep 2010, 59:258-261.
2. Nuorti JP, Whitney CG, . Centers for Disease Control and Prevention (CDC) Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010, 59:1-18. Centers for Disease Control and Prevention (CDC).
3. Rubin JL, McGarry LJ, Strutton DR, Klugman KP, Pelton SI, Gilmore KE, Weinstein MC. Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States. Vaccine 2010, 28:7634-7643. 10.1016/j.vaccine.2010.09.049, 20883739.
4. Invasive pneumococcal disease and 13-valent pneumococcal conjugate vaccine (PCV13) coverage among children aged ≤59 months - selected U.S. regions, 2010-2011. Morbid Mortal Wkly Rep 2011, 60:1477-1481.
5. Health Advisory: Fatal vaccine-preventable pneumococcal disease http://www.cdph.ca.gov/programs/immunize/Documents/HealthAdvisoryPneumococcal201108.pdf.
6. Estimated vaccination coverage with individual vaccines and selected vaccination series among children 19-35 months of age by state , , http://www.cdc.gov/Vaccines/stats-surv/nis/tables/07/tab03_antigen_state.xls; Q1/2007-Q4/2007.
7. Nuorti JP, Martin SW, Smith PJ, Moran JS, Schwartz B. Uptake of pneumococcal conjugate vaccine among children in the 1998-2002 United States birth cohorts. Am J Prev Med 2008, 34:46-53. 10.1016/j.amepre.2007.09.028, 18083450.